SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the

Sutro Biopharma (NASDAQ: STRO - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Rep

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperfor

Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and

Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces chall

Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dos

Gainers BioVie (NASDAQ:BIVI) shares increased by 39.4% to $1.77 during Wednesday's regular sess

Dow Jones up 0.1%, NASDAQ up 0.47%, S&P 500 up 0.24%. Tech stocks up 1.1%, communication service

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.33) per share which missed the analys

– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses

Wall Street analysts reshuffled their ratings on Friday with some bold calls that could move money f

Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ: STRO) by 4

Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rati

Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overwei

U.S. stock futures lower with Nasdaq down 200 points. XP Inc (XP) falls after reporting lower-than-e

Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial

Leerink Partners maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and raises the price ta

Wedbush analyst David Nierengarten upgrades Sutro Biopharma (NASDAQ:STRO) from Neutral to Outperf

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after stro

Analysts change outlook on top Wall Street names. Piper Sandler cuts target for Figma to $30, Roth C

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst

– On track to report initial safety, PK and early activity from Phase 1 dose-escalation trial of STR

Top analysts change outlook on top names, including upgrades, downgrades, and initiations. Check out

Pre-Market Stock Futures: Futures are trading higher this morning after a messy Wednesday trading se

Mizuho analyst Salim Syed initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Outperform r

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperfor

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid t

STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid t

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report)'s stock price traded up 10.4% on Friday after

Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperfor

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

Deutsche Bank analyst James Shin maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises th

Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See ful

Top Wall Street analysts upgraded STRO, JKS, AJG, ECL, RL stocks. See analysts' ratings and pric

Wells Fargo analyst Eva Fortea Verdejo upgrades Sutro Biopharma (NASDAQ:STRO) from Equal-Weight t

HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Sutro Biopharma (NASDAQ:STRO) from N

Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(5.29) per share which missed the analys

– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC;

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given an average recommendation of "

Sutro Biopharma is an early-stage ADC developer, trading at a $406m market cap after a strong 6-mont

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the C

Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume.

Citizens analyst Reni Benjamin upgrades Sutro Biopharma (NASDAQ:STRO) from Market Perform to Mark

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (NASDAQ: STRO - Get Free Report) has been given a consensus recommendation of

HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with